AnnJi Pharmaceutical Co. Ltd.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
AnnJi Pharmaceutical Co. Ltd. is a clinical-stage pharmaceutical company focusing on developing first-in-class and best-in-class small molecules innovative therapeutics to improve the quality of life of patients with neglected diseases.
The choices of therapeutic targets are mechanistically driven based on:
1. Androgen Receptor Degradation Enhancer (ARDE) for the treatment of skin disorders
2. Nrf2 Activator for PolyQ neurodegenerative diseases
3. Histone Deacetylase 6 Inhibitor (HDAC6i) for peripheral neuropathy and fibrotic diseases

AnnJi’s current leading pipelines target several unmet medical needs:
AJ101 for inflammatory skin disorders, such as acne vulgaris, psoriasis and alopecia;
AJ201 for rare polyglutamine (polyQ) diseases, such as Kennedy’s disease (spinal and bulbar muscular atrophy, SBMA) and Huntington’s disease (HD);
AJ302 for chemotherapy-induced peripheral neuropathy (CIPN) and
AJ303 for fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Taiwan
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
AJ101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
photo
Director, Business Development
AnnJi Pharmaceutical